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Best practice guidelines and recommendations
on the molecular diagnosis of myotonic dystrophy
types 1 and 2
Erik-Jan Kamsteeg1, Wolfram Kress2, Claudio Catalli3, Jens M Hertz4, Martina Witsch-Baumgartner5,
Michael F Buckley1, Baziel GM van Engelen6, Marianne Schwartz7 and Hans Scheffer*,1
Myotonic dystrophy is an autosomal dominant, multisystem disorder that is characterized by myotonic myopathy. The symptoms
and severity of myotonic dystrophy type l (DM1) ranges from severe and congenital forms, which frequently result in death
because of respiratory deficiency, through to late-onset baldness and cataract. In adult patients, cardiac conduction
abnormalities may occur and cause a shorter life span. In subsequent generations, the symptoms in DM1 may present at an
earlier age and have a more severe course (anticipation). In myotonic dystrophy type 2 (DM2), no anticipation is described, but
cardiac conduction abnormalities as in DM1 are observed and patients with DM2 additionally have muscle pain and stiffness.
Both DM1 and DM2 are caused by unstable DNA repeats in untranslated regions of different genes: A (CTG)n repeat in the
3’-UTR of the DMPK gene and a (CCTG)n repeat in intron 1 of the CNBP (formerly ZNF9) gene, respectively. The length of the
(CTG)n repeat expansion in DM1 correlates with disease severity and age of onset. Nevertheless, these repeat sizes have limited
predictive values on individual bases. Because of the disease characteristics in DM1 and DM2, appropriate molecular testing
and reporting is very important for the optimal counseling in myotonic dystrophy. Here, we describe best practice guidelines
for clinical molecular genetic analysis and reporting in DM1 and DM2, including presymptomatic and prenatal testing.
European Journal of Human Genetics (2012) 20, 1203–1208; doi:10.1038/ejhg.2012.108; published online 30 May 2012
MYOTONIC DYSTROPHY TYPES 1 AND 2
Myotonic dystrophy (DM) is an autosomal dominant, multisystem
disorder that is characterized by myotonic myopathy with associated
abnormalities in other organs.1 DM is clinically heterogeneous, and at
least two types can be distinguished: DM type 1 (DM1; Steinert
disease), which can be subdivided into four clinical subgroups, and
DM type 2 (DM2; proximal myotonic myopathy (PROMM), or
Ricker syndrome). DM1 is the most common form of muscular
dystrophy in adults with an estimated incidence of 1:8000.2 The
incidence for DM2 seems to be much lower than for DM1 and
appears to be population dependent, reaching a higher incidence in
Germany and Finland3 with an incidence similar to that of DM1.
Despite the comparable core diagnostic features and multi-organ
involvement, there are specific clinical features of DM1 and DM2,
which enable them to be distinguished.
Myotonic dystrophy type 1
There is a wide range of symptoms in DM1, ranging from mild
features, such as baldness and cataracts, to very severe features
including muscle weakness and cardiac conduction defects. Many of
the severely affected patients die of cardiac failure or respiratory
distress. The cardiac involvement in DM1 may range between
asymptomatic ECG abnormalities to sudden cardiac death.4
From a clinical perspective DM1 may be classified into four
different subtypes: (i) mild; (ii) classical; (iii) juvenile and (iv)
congenital types: (i) mild DM1: mildly symptomatic patients may
have premature cataracts and baldness as the sole clinical features.
A late-onset myopathy may develop and myotonia may only be
detectable by electromyography. Cardiac conduction abnormalities
may arise and result in a shorter life span. (ii) Classical or adult-onset
DM1: The age of onset is typically in the second or third decade of life.
The most frequent symptoms are distal weakness, involving the long
finger flexors of the arms and the dorsiflexors of the legs, leading to
symptoms relating to the strength of hand grasping and an increased
incidence of stumbling. In addition patients may have cataracts,
baldness and cardiac conduction abnormalities as in minimal DM1.
Clinical myotonia, gastro-intestinal symptoms and fatigue may also
occur. Apathy, lack of initiative, daytime sleepiness and experience
fatigue can be distressing to DM1-patients, their partners and other
family members. These features have a significant impact on quality
of life. (iii) Juvenile DM1: this form resembles the classical form of
myotonic dystrophy. However, it is more clearly associated with
cognitive and behavioral abnormalities, for example, difficulties in
learning and socialization at school. Muscle involvement may
be minimal in the juvenile presentation. (iv) Congenital DM1.
Polyhydramnios and poor fetal movements precede the birth of an
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infant with congenital DM1. The affected parent is nearly always
the mother and congenital DM1 occurs in a quarter of offspring
of affected DM1 mothers.2 The infant is typically a floppy baby
with failure to thrive and severe respiratory distress. Facial and jaw
muscles are weak and produce a tented upper lip with difficulties
in feeding and suckling. Clubfeet and joint contractures are
also common. Myotonia is typically absent clinically, and may be
difficult to detect initially even on EMG. Mental retardation and
developmental delay are common. There is a high mortality rate
in the perinatal period. Muscle biopsies of patients with congenital
DM1 may reveal only variability in fiber size and centralization
of nuclei. However, none of the characteristics found in muscle
biopsies of patients with classical or adult-onset DM1 myotonic
dystrophy are present. Therefore, in order to confirm a clinical
suspicion of congenital DM1, the diagnosis can only be established
by DNA analysis.1,2
Myotonic dystrophy type 2
The DM2 phenotype has some similarities to that of DM1 (myotonia,
cataract and muscle weakness), but also some differences. The typical
clinical presentation of DM2 is that of predominantly proximal
muscle weakness, with muscle pain but no atrophy (PROMM
phenotype).5 Myotonia is variable (both clinically as well as on
EMG). However, in its mildest form, DM2 can be difficult to
recognize. Conversely, DM2 may also present with severe proximal
muscle involvement with remarkable muscle wasting without clinical
myotonia.6,7 The mean age of onset for DM2 is in the third and
fourth decades of life. Unlike DM1, no congenital form of DM2 has
been described.
In summary, the clinical challenge in DM1 lies in supplying
optimal care for this multisystem disease, whereas in DM2 it is also
a diagnostic challenge to recognize the disease. Detection of a repeat
expansion in the DMPK gene and the CNBP gene is fast, inexpensive
and reliable. Both the clinical sensitivity and the clinical specificity
are 499% (Eurogentest clinical utility gene cards: http://www.
eurogentest.org).
MOLECULAR GENETIC DEFECTS IN MYOTONIC DYSTROPHY
TYPES 1 AND 2
DM1 (MIM #160900) is caused by a (CTG)n repeat expansion in the
3’-untranslated region of the DMPK gene located within chromosome
band 19q13.3.8–10 DM2 (MIM #602668) is caused by a large (CCTG)n
repeat expansion in intron l of the CNBP (formerly known as ZNF9)
gene, at chromosome 3q21.11–13
The number of CTG-repeat units in stable nonpathogenic DMPK
alleles ranges from 5 to 35.1,14 (In previous publications, we have
used 37 as limit of the largest normal allele size. Because of the
use of 35 by other bodies, such as ‘The International Myotonic
Dystrophy Consortium (IDMC),1 this was adapted for congruity.
As repeats of 36 and 37 have not been detected in a large
group of individuals,14 this adaptation is not anticipated to
have any consequences for past or future reporting). DMPK alleles
containing over 35 CTG-repeat units demonstrate a length-dependent
risk of instability on transmission. Alleles containing a CTG-repeat
with a length of 51–150 may be either asymptomatic or may give
rise to minimal or classical DM1. A more severe DM1 phenotype is
associated with DMPK alleles with sizes 4150 CTG-repeat units.
An overview of the general phenotype–genotype correlation1,14–16
is provided in Table 1.
Thus, the severity of the disease and the age of onset is correlated
with the number of CTG-repeat units within the expanded DNA
sequence, although the individual variability is high.15–19 An
increasing number of CTG-repeat units within the DMPK gene in
successive generations in a family is associated with an earlier onset of
the disorder. This phenomenon is termed ‘anticipation’.20 For DM1
parental sex has an important role in determining the level of
intergenerational instability once the repeat size exceeds 150
repeats.15 Congenital DM1 is almost exclusively transmitted by the
mother, a phenomenon that is not well understood.
In less than 5% of DM1 patients, the otherwise pure CTG-repeat
tract is interrupted by GGC, CCG or CTC repeats.21,22 Despite the
reported unusual disease characteristics in some of these patients, the
clinical relevance of such interruption remains to be established.
The CNBP gene harbors a complex-repeat tract (TG)n(TCTG)n
(CCTG)n, and expansions of the CCTG-repeat array within this
complex repeat are the cause of DM2.11 Nonpathogenic alleles
contain to 26 CCTG-repeat units. In DM2 patients, the range
of repeat units is extremely wide, ranging from about 75 to over
11 000 units, with a mean of 5000.11 Unlike in DM1, no significant
association between the age of onset and the number of CCTG-
repeat unit has been detected in DM2.23 Likewise, anticipation has
not been observed in DM2 families.
MOLECULAR DIAGNOSTIC ANALYSIS IN DM1 AND DM2
The first step in the molecular analysis of DM1 or DM2 is to analyze
whether an individual has two alleles with a low number of repeats
that can easily be detected by conventional PCR and fragment-length
analysis. If only one allele size is detected, subsequent techniques
such as repeat-primed PCR and or Southern blotting of genomic
DNA or long-range PCR products are used to detect possible
repeat expansions. PCR primers used by different laboratories are
listed in Table 2.
In prenatal DM1 testing, analysis of DNA from the mother is also
required to exclude maternal contamination in the fetal samples. The
combination of these data allows interpretation and reporting. The
delivery of diagnostic molecular genetics services for pre/post-natal
DM requires in-house validation, on-going quality control processes
and the supervision by a clinical molecular geneticist.
Molecular diagnostic tests in DM1
PCR and fragment-length analysis. In the lower range of DM1
expansions, the best analytical method is PCR. Alleles containing
between 5 and 100 to 125 CTG-repeat units can be detected and
characterized using synthetic fluorescently-labeled primers flanking
the CTG-repeat region, followed by direct analysis of the length of the
amplified products by capillary electrophoresis.
Triplet-repeat Primed (TP)-PCR. The TP-PCR is a PCR with three
primers, where one lies outside the repeat, one within the repeat
(which is added in limiting amounts) that also has a sequence-tail
Table 1 Size ranges of CTG repeats in the DMPK gene and
corresponding most common phenotypes
Number of repeats Stability of repeat DM phenotype
5–35 (normal range) Stable No DM
36–50 May be unstable No DM
51–150 Unstable No, minimal or classical DM
4150 Unstable Classical, juvenile or congenital DM
Abbreviation: DM, myotonic dystrophy.
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complementary to the third, universal, and fluorescently-labeled
primer.24 This will result in a mixture of PCR fragments of
different sizes that can be analyzed by capillary electrophoresis.
Although expansions in all size ranges can be detected by TP-PCR,
no reliable information about the length of the expanded repeat will
be obtained because of extinction of the signal in the higher size
region. In DM1 expansion analysis (see Figure 1a for an example), the
TP-PCR has proven to be an accurate technique. Nevertheless, the
presence of rare interruptions of the otherwise pure CTG repeat21,22
may result in aberrant patterns or failure to detect expansions with
TP-PCR.25 Therefore, to exclude false-negative reports, an additional
test (such as a TP-PCR at the other repeat end or Southern blotting)
is strongly recommended.
Southern blotting of long-range PCR-products. This Southern blot
method (for an example, see Figure 1b) requires precise PCR
conditions to ensure the amplification of larger fragments, monitored
by using appropriate positive and negative (healthy) controls,
followed by probing with an end-labeled (CTG)x (where x is 5 or
more) probe.26 On these Southern blots, expanded DMPK alleles will
appear in virtually all cases as smears or multiple fragments, which is
(in part) owing to somatic heterogeneity. Also, as with the TP-PCR,
interrupted repeats may remain undetectable under certain
conditions. Therefore, conditions that ensure the amplification of
CG-rich and long templates is recommended.
Southern blotting of genomic DNA. Southern blotting of genomic
DNA (for an example, see Figure 1c), digested with an appropriate
restriction enzyme (EcoRI, BamHI, NcoI or BglI), has been the gold
standard for the detection of DMPK alleles containing 100 CTG-
repeat units and over since the identification of the DMPK gene.8
Several different probes have been reported for hybridization.8,9,27,28
However, this procedure is time-consuming and has been replaced by
TP-PCR and/or by Southern blotting of long-range PCR-products in
most diagnostic centers.
Indirect DNA analysis. Though direct detection of expansions in the
DMPK gene is the most straightforward technique, indirect DNA
analysis is useful in some cases where confirmation of result is
Table 2 Primer sequences used for myotonic dystrophy tests
Gene Location Purpose Center Sequence (5 0-3 0)
DMPK Forward PCR C cttcccaggcctgcagtttgcccatc
Reverse PCR C gaacggggctcgaagggtccttgtagc
Forward PCR N ctcgaagggtccttgtagcc
Forward TP-PCR N gaagggtccttgtagccgggaa
Forward LR-PCR N ccgttggaagactgagtg
Reverse PCR N tgcacaagaaagctttgcac
Reverse TP-PCR N tacgcatcccagtttgagacgcagcagcagcagcag
Universal TP-PCR N tacgcatcccagtttgagacg
Reverse LR-PCR N ctggccgaaagaaagaaatg
CNBP Forward PCR W ggccttataaccatgcaaatg a
Forward PCR N ttggacttggaatgagtgaatg
Forward LR-PCR N/W ggccttataaccatgcaaatg a
Reverse (LR)-PCR/
QP-PCR
W/R gcctaggggacaaagtgag(a) a
Reverse PCR N agccgagatcataccactgc
Reverse LR-PCR/
QP-PCR
N agcctaggggacaaagtgag
Forward QP-PCR N/W/R tacgcatcccagtttgagacgcctgcctgcctgcctgcctg
Universal QP-PCR R tacgcatcccagtttgagacg
Abbreviations: C, Copenhagen; LR, long-range, N, Nijmegen; QP, quadruplet-repeat primed;
R, Rome; TP: triplet-repeat primed, W, Wu¨rzburg
Repeat sequences are underlined.
aThese primers amplify the CL3N58 marker, which is defined as a CAGG repeat and is the
reverse complement of the CCTG repeat in the CNBP gene.
(a) A rare polymorphism affecting this base was detected on a CNBP allele that also harbors
a CCTG expansion (E Ormshaw, SW Thames Molecular Genetics Diagnostic Laboratory,
London, UK, personal communication).
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Figure 1 Molecular diagnostic tests in myotonic dystrophy type 1.
(a) Fragment-length analysis of TP-PCR products of the CTG repeat in the
DMPK gene. Fluorescently-labeled PCR products of a healthy individual
having two normal alleles (5 and 13 CTG repeats; top panel) and an
affected individual (bottom panel) with one normal allele (5 repeats)
and one expanded allele were separated by capillary electrophoresis.
(b) Southern blotting of long-range PCR-products of the CTG repeat in the
DMPK gene. Long-range PCR fragments were subjected to to agarose gel
electophoresis and capillary transfer to a nylon membrane. Subsequently,
the membrane was hybridized with a labeled (CAG)5 probe. Visualized
repeats were from a healthy control (lane 2), a patient with a heterozygous
expansion in the size range of 51–150 repeats (lane 1), and a patient with
a heterozygous expansion in the size range over 150 repeats (lane 3).
(c) Southern blotting of genomic DNA probed for the DMPK gene. Genomic
DNA samples were fragmented using BglI and subjected to electophoresis
and capillary blotting to a nylon membrane. Subsequently, the membrane
was hybridized with a 32P-labeled probe for the DMPK gene. Visualized
fragments were from a healthy control (1), and patients with one normal
and one expanded allele (2 and 3). Estimation of the lengths of the repeat
expansions can be done using the size markers (M). Normal sized alleles
and expansions are indicated.
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required by a separate technique. Polymorphic markers surrounding
the DMPK gene that can be used for such an indirect analysis are
outlined in Table 3.
Molecular diagnostic tests in DM2
Owing to the extreme expansion sizes (to 440 kb) that may be
present in DM2 patients,11 it is important to ensure isolation of high
molecular weight DNA from peripheral blood.
PCR and fragment-length analysis. In the lower range of DM2 repeat
sizes, the best analytical method is PCR. Such alleles can be detected
and characterized using synthetic, fluorescently-labeled primers flank-
ing the complex-repeat region (also known as the CL3N58 repeat
marker), followed by direct sizing of the amplified products by
capillary electrophoresis. Because of the variability of the different
units of this complex (TG)n(TCTG)n(CCTG)n, repeat, the precise
length of the pathogenic CCTG unit within this repeat can only
be determined by sequencing. However, as the difference between
normal alleles (repeats to 26 CCTG units) and disease-associated
alleles (75 units and more, with a mean of 5000) almost always is
evident, exact sizing is not routinely performed.
Quadruplet-repeat primed (QP)-PCR. This technique, is similar to
the TP-PCR used for DM1, but now with a primer in the tetra-
nucleotide repeat;29 see Figure 2a for an example). In theory,
the QP-PCR will detect expansions independent of their lengths.
Although expansions in all size ranges can in theory be detected by
QP-PCR, no reliable information about the length of the expanded
repeat will be obtained because of extinction of the signal in the
higher size region.
Southern blotting of long-range PCR-products. This Southern blot
method (see Figure 2b for an example) requires precise PCR
conditions to ensure the amplification of larger fragments, monitored
by using appropriate positive and negative (healthy) controls. Southern
blotting of these fragments is followed by probing with an end-labeled
(CCTG)5or6 probe.
30 On these Southern blots, expanded CNBP alleles
will appear in virtually all cases as smears or multiple fragments,
which is (in part) due to somatic heterogeneity. Using this technique
in DM2 diagnostics, one should be aware of false positives, probably
occurring because of background signals of total genomic DNA after
overexposure of the blot signals. Therefore, negative controls (healthy
subjects) should be free of smears on the blot.
Southern blotting of genomic DNA. Direct analysis by Southern
blotting (for an example, see Figure 2c), after digestion of genomic
DNA with EcoRI, TaqI or alternative enzymes, followed by hybridiza-
tion using the CL3N58 probe, was the first method used for studying
the DM2 mutation.11 Owing to the extreme size of the expansion and
the level of somatic instability as well as cross hybridizations of the
probe, only a very heterogeneous smear can be visualized, limiting the
sensitivity of this test to B80% of known carriers when applied
without additional precautions. Several improvements of the basic
Table 3 Markers flanking the DMPK gene
Marker
Location in bp
(Human RefMap)
Position in cM
(Genethon)
Allele
size (bp)
D19S217 40,713,572–40,713,794 67.8 219–233
D19S574 41,555,837–4,1556,038 69.20 164–202
D19S918 NA 69.50 140–182
D19S219 42,423,170–42,423,347 69.90 160–190
DMPK 42,701,722–42,714,534 70.14
D19S902 44,758,758–44,758,960 76.20 199–217
Abbreviation: NA, not applicable.
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Figure 2 Molecular diagnostic tests in myotonic dystrophy type 2. (a) Fragment-length analysis of QP-PCR products of the CCTG repeat in the CNBP gene.
Fluorescently-labeled PCR products of a healthy individual (top panel) and an affected individual (bottom panel) with one normal allele and one expanded
allele (4100 repeats) were separated by capillary electrophoresis. (b) Southern blotting of long-range PCR products of the CCTG repeat in the CNBP gene.
Long-range PCR fragments were subjected to agarose gel electophoresis and capillary transfer to a nylon membrane. Subsequently, the membrane was
hybridized with an end-labeled (CAGG)5 probe. Visualized repeats were from a healthy compound heterozygous individual (lane 1) and a patients (lane 2)
with one normal and one expanded allele. (c) Southern blotting of genomic DNA probed for the CNBP gene. Genomic DNA samples were fragmented using
EcoRI and subjected to electophoresis and capillary blotting to a nylon membrane. Subsequently, the membrane was hybridized with a mixture of the
CL3N58 (within the CNBP gene) and a reference probe (both 32P-labeled). Visualized fragments were from a healthy control (lane 1), and patients with one
normal and one expanded allele (lanes 2 and 3). Note the decrease in intensity of the normal allele in the patients with an expansion, when compared with
the control probe signal. Normal sized CNPB alleles and expansions, as well as the reference probe, are indicated.
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protocol can be adopted in order to minimize possible sources of
false-negative results, such as the inclusion of a reference probe to
allow quantification of the non-expanded alleles.31 However, like in
DM1 analysis, this procedure is time-consuming and has been
replaced by QP-PCR or by Southern blotting of long-range PCR-
products by most diagnostic laboratories.
INTERPRETATION AND REPORTING
Myotonic dystrophy type 1
There is an association between CTG-repeat size and the age of onset
and severity of symptoms (see Table 1). However, there is a large
inter-individual variability and one should be very cautious with
phenotypic predictions in individual cases.15–19 Therefore, the
boundaries in repeat lengths of the four groups in Table 1 should
not be interpreted too rigidly.
In DM, it is sufficient to report the size range of a repeat rather
than an exact repeat length, that is, ‘a normal (CTG)n repeat length of
(n¼ 5–35)’ or ‘a large expansion of the (CTG)n repeat (n 4150)’.
Whenever an exact allele size is reported it should be accompanied by
a statement of the testing laboratory’s uncertainty of measurement in
the sizing.
For the reporting of exact normal allele sizes (n¼ 5–35), which are
determined by PCR and subsequent capillary electrophoresis, internal
control standards from sequence-verified samples should be included.
Alternatively, exact allele sizes can be obtained by DNA sequence
analysis. For larger expansions, a range of repeat lengths should be
estimated based on comparisons with molecular weight standards
and/or characterized control samples.
The result of the appropriate tests will lead to one of the following
possibilities and recommended reporting guidelines. (i) No expansion
(homozygous or compound heterozygous for a normal allele size):
This excludes the diagnosis of DM1. When it concerns a fetus, it is
not affected. (ii) A heterozygous expansion in the size range of 36–50
repeats: (a) This excludes the diagnosis of DM1; when it concerns a
fetus, it is not affected, (b) repeats of this length may or may not
expand in future generations and (c) relatives (including offspring)
of the counselee may be at risk of developing DM1. Therefore,
they should be offered counseling. An offer of repeat-length
analysis to those relatives at risk is warranted. (iii) A heterozygous
expansion in the size range of 51–150 repeats: (a) when symptoms
are evident, the diagnosis of DM1 is confirmed, (b) When symptoms
of DM1 are not evident (asymptomatic family member or fetus),
the individual is at risk of developing DM1, although individuals
with a repeat expansion of this size may also remain symptomless,
(c) counselees of reproductive age, and especially women, are at
risk of having children with the congenital form of DM1 and
(d) relatives (including offspring) of the counselee may be at risk
of developing DM1. Owing to anticipation in DM1, offspring may
be more severely affected. Relatives should therefore be offered
counseling. An offer of repeat-length analysis to those relatives is
warranted. (iv) A heterozygous expansion with a size over 150 repeats:
(a) when symptoms are evident, the diagnosis of DM1 is confirmed,
(b) when symptoms of DM1 are not evident (asymptomatic family
member), the individual is at risk of developing DM1, although
individuals with a repeat expansion of this size may also remain
symptomless, (c) when it concerns a fetus, it is very likely to be
affected and has a high risk to be more severely affected than
the affected parent, (d) counselees in the reproductive age,
and especially women, are at risk of having children with the
congenital form of DM1 and (e) relatives (including offspring)
of the counselee may be at risk of developing DM1. Because of
anticipation in DM1, the offspring may be more severely affected.
Therefore, relatives should be offered counseling. An offer of repeat-
length analysis to those relatives is warranted.
A tabular format of the reporting guidelines is available as
Supplementary Data.
Myotonic dystrophy type 2
As variability in the sizes of the different subunits of the complex
repeat, (TG)n(TCTG)n(CCTG)n, in the CNBP gene exists, the precise
length of the pathogenic CCTG unit within this repeat can only be
determined by DNA sequencing. However, as repeats to 26 CCTG
units are considered to be nonpathogenic, whereas disease-associated
alleles contain 75 units and more, exact repeat sizing is not routinely
performed. Experiences from several laboratories suggest that most
frequently encountered pathogenic repeats reside in the high range
(with a mean of 5000 repeats). Alleles between 26 and 75 CCTG units
(gray area) are very rare but have been reported.32 Their clinical
relevance, however, is not well characterized.
If reporting allele sizes (rather than a range), estimates of the
uncertainty of measurement in the sizing in the testing laboratory
should be reported. For allele sizes determined by PCR and
subsequent capillary electrophoresis, a deviation of two repeat units
may be present. For (larger) expansions, a range of repeat lengths
should be estimated on basis of markers and/or control samples.
However, in the reports of most laboratories the exact length of the
repeat is not specified. The result of appropriate testing leads to one
of the following possibilities and subsequent recommended reporting
guidelines: (i) no expansion (homozygous or compound hetero-
zygous for a normal allele size): this excludes the diagnosis of DM2.
(ii) A heterozygous expansion of over 75 CCTG-repeat units: (a) the
diagnosis of DM2 is confirmed and (b) relatives (including offspring)
of the counselee may be at risk of developing DM2. Therefore, they
should be offered counseling. An offer of repeat-length analysis to
those relatives is warranted.
A tabular format of the reporting guidelines is available as
Supplementary Data.
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